During the last session, Inovio Pharmaceuticals Inc (NASDAQ:INO)’s traded shares were 0.77 million, with the beta value of the company hitting 1.31. At the end of the trading day, the stock’s price was $1.96, reflecting an intraday gain of 0.51% or $0.01. The 52-week high for the INO share is $12.33, that puts it down -529.08 from that peak though still a striking 27.55% gain since the share price plummeted to a 52-week low of $1.42. The company’s market capitalization is $71.89M, and the average intraday trading volume over the past 10 days was 0.73 million shares, and the average trade volume was 666.12K shares over the past three months.
Inovio Pharmaceuticals Inc (INO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.80. INO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Inovio Pharmaceuticals Inc (NASDAQ:INO) trade information
Inovio Pharmaceuticals Inc (INO) registered a 0.51% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.51% in intraday trading to $1.96, hitting a weekly high. The stock’s 5-day price performance is -5.77%, and it has moved by -7.98% in 30 days. Based on these gigs, the overall price performance for the year is -78.08%. The short interest in Inovio Pharmaceuticals Inc (NASDAQ:INO) is 6.57 million shares and it means that shorts have 11.65 day(s) to cover.
The consensus price target of analysts on Wall Street is $20, which implies an increase of 90.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $40 respectively. As a result, INO is trading at a discount of -1940.82% off the target high and -308.16% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 22.92%. While earnings are projected to return 47.65% in 2025, the next five years will return 39.23% per annum.
INO Dividends
Inovio Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Inovio Pharmaceuticals Inc (NASDAQ:INO)’s Major holders
Inovio Pharmaceuticals Inc insiders own 0.73% of total outstanding shares while institutional holders control 37.28%, with the float percentage being 37.56%. DEEP TRACK CAPITAL, LP is the largest shareholder of the company, while 146.0 institutions own stock in it. As of 2024-06-30, the company held over 2.07 million shares (or 7.5988% of all shares), a total value of $16.7 million in shares.
The next largest institutional holding, with 1.71 million shares, is of BLACKROCK INC.’s that is approximately 6.2741% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $13.79 million.
